JOP20210220A1 - معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى - Google Patents
معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرىInfo
- Publication number
- JOP20210220A1 JOP20210220A1 JOP/2021/0220A JOP20210220A JOP20210220A1 JO P20210220 A1 JOP20210220 A1 JO P20210220A1 JO P20210220 A JOP20210220 A JO P20210220A JO P20210220 A1 JOP20210220 A1 JO P20210220A1
- Authority
- JO
- Jordan
- Prior art keywords
- immune cells
- antibody
- treatment
- combination
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804721P | 2019-02-12 | 2019-02-12 | |
| PCT/US2019/066648 WO2020167376A1 (en) | 2019-02-12 | 2019-12-16 | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210220A1 true JOP20210220A1 (ar) | 2023-01-30 |
Family
ID=69182616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0220A JOP20210220A1 (ar) | 2019-02-12 | 2021-08-11 | معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220213223A1 (https=) |
| EP (1) | EP3923954A1 (https=) |
| JP (2) | JP2022520572A (https=) |
| KR (1) | KR20210143752A (https=) |
| CN (2) | CN119950702A (https=) |
| AU (2) | AU2019429147B2 (https=) |
| BR (1) | BR112021015870A2 (https=) |
| CA (1) | CA3129890A1 (https=) |
| CL (1) | CL2021002140A1 (https=) |
| EA (1) | EA202192235A1 (https=) |
| IL (1) | IL285480A (https=) |
| JO (1) | JOP20210220A1 (https=) |
| MA (1) | MA54923A (https=) |
| MX (1) | MX2021009687A (https=) |
| PH (1) | PH12021551960A1 (https=) |
| SG (1) | SG11202108767PA (https=) |
| WO (1) | WO2020167376A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552135A1 (en) | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SG10201604104PA (en) | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| MX389805B (es) * | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| WO2018005967A1 (en) * | 2016-06-30 | 2018-01-04 | Prothena Therapeutics Limited | Compositions for treating amyloidosis |
-
2019
- 2019-12-16 AU AU2019429147A patent/AU2019429147B2/en active Active
- 2019-12-16 BR BR112021015870A patent/BR112021015870A2/pt unknown
- 2019-12-16 EA EA202192235A patent/EA202192235A1/ru unknown
- 2019-12-16 JP JP2021547075A patent/JP2022520572A/ja not_active Withdrawn
- 2019-12-16 CN CN202510068246.0A patent/CN119950702A/zh active Pending
- 2019-12-16 EP EP19839484.3A patent/EP3923954A1/en active Pending
- 2019-12-16 PH PH1/2021/551960A patent/PH12021551960A1/en unknown
- 2019-12-16 MX MX2021009687A patent/MX2021009687A/es unknown
- 2019-12-16 MA MA054923A patent/MA54923A/fr unknown
- 2019-12-16 WO PCT/US2019/066648 patent/WO2020167376A1/en not_active Ceased
- 2019-12-16 CN CN201980094744.5A patent/CN113924099A/zh active Pending
- 2019-12-16 US US17/429,876 patent/US20220213223A1/en not_active Abandoned
- 2019-12-16 SG SG11202108767PA patent/SG11202108767PA/en unknown
- 2019-12-16 CA CA3129890A patent/CA3129890A1/en active Pending
- 2019-12-16 KR KR1020217029118A patent/KR20210143752A/ko not_active Ceased
-
2021
- 2021-08-09 IL IL285480A patent/IL285480A/en unknown
- 2021-08-11 JO JOP/2021/0220A patent/JOP20210220A1/ar unknown
- 2021-08-12 CL CL2021002140A patent/CL2021002140A1/es unknown
-
2024
- 2024-10-18 US US18/920,634 patent/US20250075007A1/en active Pending
- 2024-11-12 JP JP2024197437A patent/JP2025015588A/ja active Pending
-
2025
- 2025-02-13 AU AU2025200997A patent/AU2025200997A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MA54923A (fr) | 2021-12-22 |
| JP2022520572A (ja) | 2022-03-31 |
| CN119950702A (zh) | 2025-05-09 |
| BR112021015870A2 (pt) | 2021-11-03 |
| MX2021009687A (es) | 2021-12-10 |
| SG11202108767PA (en) | 2021-09-29 |
| IL285480A (en) | 2021-09-30 |
| JP2025015588A (ja) | 2025-01-30 |
| CA3129890A1 (en) | 2020-08-20 |
| CN113924099A (zh) | 2022-01-11 |
| AU2019429147A1 (en) | 2021-09-09 |
| US20220213223A1 (en) | 2022-07-07 |
| EP3923954A1 (en) | 2021-12-22 |
| PH12021551960A1 (en) | 2022-07-18 |
| WO2020167376A8 (en) | 2020-10-29 |
| CL2021002140A1 (es) | 2022-04-18 |
| AU2019429147B2 (en) | 2024-11-14 |
| EA202192235A1 (ru) | 2022-01-19 |
| WO2020167376A1 (en) | 2020-08-20 |
| AU2025200997A1 (en) | 2025-03-13 |
| KR20210143752A (ko) | 2021-11-29 |
| US20250075007A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111712522A (zh) | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JOP20210220A1 (ar) | معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى | |
| ATE452147T1 (de) | Antikörper mit korrigierten cdr | |
| AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| ATE434626T1 (de) | Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen | |
| ZA201901781B (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| AR114112A1 (es) | Anticuerpos de glipicano 3 y conjugados de los mismos | |
| MX2022001111A (es) | Anticuerpo anti-pd-1 y uso farmaceutico del mismo. | |
| CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
| MX2023010687A (es) | Anticuerpos monoclonales anti cd47 y usos de los mismos. | |
| MX2021015763A (es) | Polipeptidos. | |
| PH12021553109A1 (en) | Humanized antibody molecules to cd138 and uses thereof | |
| MX2022002505A (es) | Anticuerpo monoclonal anti-cd47 y uso del mismo. | |
| ZA202001114B (en) | Dynamic human heavy chain antibody libraries | |
| EP4112723C0 (en) | ANTI-KPC TYPE CARBAPENEMASE HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND ITS APPLICATION | |
| MX382703B (es) | ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. | |
| EP4112722C0 (en) | ANTI-VIM CARBAPENEMASE HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND APPLICATION | |
| ZA202001112B (en) | Dynamic human antibody light chain libraries | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
| CL2024004032A1 (es) | Polipéptido de unión al antígeno anti-sars-cov-2; y complejo de polipéptidos de unión a antígeno. | |
| MX2021012652A (es) | Metodos para el tratamiento de sujetos con artritis psoriasica. | |
| HK40067146A (en) | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells | |
| HK40067140A (en) | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells | |
| EA201991510A1 (ru) | Каркасы антител для снижения агрегирования полиспецифических антител | |
| EA202092264A1 (ru) | Лечение и профилактика амилоидоза |